Arrayit Corporation Announces Microarray Platform Sale to Leading Laboratory in Israel
2013年11月22日 - 10:00PM
ビジネスワイヤ（英語）
Arrayit Corporation (OTCBB:ARYC), a life sciences and molecular
diagnostics leader, announces today that the Company has sold a
$129,548 NanoPrint™ LM60 Enterprise Level Microarray Printer to a
leading research laboratory in Tel Aviv, Israel. Arrayit NanoPrint™
instruments enable microarray manufacturing in a high-throughput
and highly automated manner using advanced linear drive motion
control and linear encoders that permit nanometer positional
resolution. Microarrays are biomedical devices that contain genes,
proteins, antibodies and other molecules from the human genome and
proteome printed at high-density on glass substrates. Patient
samples are labeled and reacted with microarrays to provide answers
to human health including the pre-symptomatic detection of cancer,
autoimmune disease, and other treatable conditions.
In 2010, Arrayit received Israeli Patent Number 153848 covering
microarray methods for DNA testing, to improve the economies of
scale in genotyping by allowing thousands of patient DNA samples to
be simultaneously tested. The NanoPrint™ sale to Tel Aviv, the
issued 848’ patent and other recent developments underscore
Arrayit’s commitment to providing its patented and proprietary
technology to Israel in furtherance of leading-edge life sciences
research, diagnostics and an increasingly advanced health care
system. The Company is currently seeking a joint-venture partner is
Israel to further expand sales in this important economy.
Arrayit recently announced a 51% year-over-year quarterly sales
increase in the third quarter ended September 30, 2013, with
profitability and a $1.48M net income improvement over 2012 for the
first nine months of this year. The Company also announced the
appointment of renowned biotech analyst Sid Taubenfeld to the Board
of Directors, the opening of the Company’s new corporate
headquarters in Sunnyvale, California USA on January 1, 2014, and
the completion of a $1M equity capital raise with funds to be used
for Company growth and expansion.
About Arrayit Corporation
Arrayit utilizes its patented and proprietary microarray
platform to lead and empower the genetic, research, pharmaceutical,
and diagnostic communities through the discovery, development and
manufacture of proprietary life science technologies and
consumables for disease prevention, treatment and cure.- Powerful
Science for LifeVisit http://arrayit.com/ for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words
such as "expect", "believe", and "should". Although we believe our
expectations are reasonable, our operations involve a number of
risks and uncertainties that are beyond our control, and these
statements may turn out not to be true. Risk factors associated
with our business, including some of the facts set forth herein,
are detailed in the Company's Form 10-K for the fiscal year ended
December 31, 2012 and in Form 10-Q for the quarterly period ended
September 30, 2013.
Investor RelationsInstitutional Marketing Services
(IMS)John Nesbett/Jennifer
Belodeau203-972-9200jnesbett@institutionalms.comjbelodeau@institutionalms.com
Arrayit (CE) (USOTC:ARYC)
過去 株価チャート
から 12 2024 まで 1 2025
Arrayit (CE) (USOTC:ARYC)
過去 株価チャート
から 1 2024 まで 1 2025
